0001104659-20-058217.txt : 20200507
0001104659-20-058217.hdr.sgml : 20200507
20200507180015
ACCESSION NUMBER: 0001104659-20-058217
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200505
FILED AS OF DATE: 20200507
DATE AS OF CHANGE: 20200507
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Chan Phillip P.
CENTRAL INDEX KEY: 0001442786
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36792
FILM NUMBER: 20857975
MAIL ADDRESS:
STREET 1: 1001 BRIGGS ROAD
STREET 2: SUITE 280
CITY: MOUNT LAUREL
STATE: NJ
ZIP: 08054
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Cytosorbents Corp
CENTRAL INDEX KEY: 0001175151
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 980373793
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7 DEER PARK DRIVE, SUITE K
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
BUSINESS PHONE: 973-329-8885
MAIL ADDRESS:
STREET 1: 7 DEER PARK DRIVE, SUITE K
CITY: MONMOUTH JUNCTION
STATE: NJ
ZIP: 08852
FORMER COMPANY:
FORMER CONFORMED NAME: MedaSorb Technologies CORP
DATE OF NAME CHANGE: 20060807
FORMER COMPANY:
FORMER CONFORMED NAME: GILDER ENTERPRISES INC
DATE OF NAME CHANGE: 20020611
4
1
tm2019006d1_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-05-05
0
0001175151
Cytosorbents Corp
CTSO
0001442786
Chan Phillip P.
C/O CYTOSORBENTS CORPORATION
7 DEER PARK DRIVE, SUITE K
MONMOUTH JUNCTION
NJ
08852
1
1
0
0
Chief Executive Officer
Common Stock
2020-05-05
4
M
0
14100
9.39
A
714682
D
Stock Option (right to buy)
3.45
2020-05-05
4
M
0
14100
0
D
2030-05-05
Common Stock
14100
0
D
Includes: (i) the following RSUs that will be settled into common stock, par value $0.0001 per share (the "Common Stock") upon vesting upon a "Change In Control" of CytoSorbents Corporation (the "Company") as defined in the Amended and Restated CytoSorbents Corporation 2014 Long-Term Incentive Plan: (a) 10,300 RSUs granted on March 15, 2018, (b) 18,700 RSUs granted on February 24, 2017, (c) 57,000 RSUs granted on June 7, 2016 and (d) 130,000 RSUs granted on April 8, 2015; (continue with footnote 2)
(ii) the following RSUs (which vest as to one-third of the award on each of the date of grant, the first anniversary of the date of grant, and the second anniversary of the date of grant, subject to the reporting person's continued service as of the applicable vesting date) and will settle into Common Stock upon vesting: (a) 40,000 RSUs granted on February 28, 2020 and unvested on the date hereof, (b) 40,000 RSUs granted on July 22, 2019 and unvested on the date hereof, and (c) 1,834 RSUs granted on March 4, 2019 and unvested on the date hereof; and (iii) 416,848 shares of Common Stock owned by the reporting person.
These stock options were originally granted on May 5, 2010 and became exercisable at the discretion of the Board of Directors of the Company based on criteria including (but not limited to) a timely completion of the sepsis trial, raising capital for the Company, and partnering and business development.
/s/ Kathleen P. Bloch attorney-in-fact for Phillip P. Chan
2020-05-07